Peter C. Adamson named global development therapeutic area head of oncology and pediatric innovation at Sanofi

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Peter Adamson

Peter C. Adamson was named global development therapeutic area head of oncology and pediatric innovation at Sanofi. Based in Cambridge, MA, Adamson will lead the global development in cancer, and will work with leaders across therapeutic areas to further pediatric drug development efforts.

Adamson joins Sanofi from the Perelman School of Medicine of the University of Pennsylvania, where he was professor of pediatrics and pharmacology, and held the Alan R. Cohen Endowed Chair in Pediatrics at Children’s Hospital of Philadelphia. For almost 10 years prior to joining Sanofi, Adamson chaired the Children’s Oncology Group, an NCI-supported international consortium of more than 220 centers that conduct clinical-translational research, including large-scale clinical trials, in children and adolescents with cancer.

Adamson is board certified in hematology/oncology and clinical pharmacology. He was appointed by President Obama to the National Cancer Advisory Board, where he continues to serve. Adamson also served on the blue-ribbon panel for the Beau Biden National Cancer Moonshot Initiative.

Table of Contents

YOU MAY BE INTERESTED IN

If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.
Undeterred by the negative topline result of its pivotal trial of Galleri, a multicancer detection test, the test’s sponsor, GRAIL, said it’s forging ahead with its plan to get FDA approval and reimbursement from CMS and private insurers.
Philip E. Castle, director of the NCI Division of Cancer Prevention, said he was disappointed to hear that GRAIL’s NHS-Galleri trial did not meet its primary endpoint of reduction in late-stage cancers.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login